Spots Global Cancer Trial Database for Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)
Official Title: A Phase 1/1b Open-label, Multicenter Clinical Study of MK-0472 as Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors.
Study ID: NCT05853367
Study Description
Brief Summary: The purpose of this study is to assess the efficacy, safety, and tolerability of MK-0472 administered as monotherapy and in combination with pembrolizumab (MK-3475) or MK-1084 in participants with histologically or cytologically confirmed diagnosis of advanced/metastatic solid tumors.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Northwestern Memorial Hospital ( Site 0002), Chicago, Illinois, United States
John Theurer Cancer Center at Hackensack University Medical Center ( Site 0001), Hackensack, New Jersey, United States
Princess Margaret Cancer Centre ( Site 0101), Toronto, Ontario, Canada
Centre Hospitalier de l'Université de Montréal-Unit for Innovative Therapies ( Site 0100), Montréal, Quebec, Canada
Hôpitaux Universitaires de Genève (HUG) ( Site 0202), Genève, Geneve, Switzerland
Cantonal Hospital St.Gallen-Oncology & Hematology ( Site 0201), st.Gallen, Sankt Gallen, Switzerland
Ospedale Regionale Bellinzona e Valli ( Site 0200), Bellinzona, Ticino, Switzerland
Contact Details
Name: Medical Director
Affiliation: Merck Sharp & Dohme LLC
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
